MDxHealth SA (NASDAQ:MDXH) Short Interest Down 68.2% in July

MDxHealth SA (NASDAQ:MDXHGet Rating) saw a large drop in short interest in July. As of July 15th, there was short interest totalling 2,100 shares, a drop of 68.2% from the June 30th total of 6,600 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 54,200 shares, the short-interest ratio is presently 0.0 days.

Institutional Investors Weigh In On MDxHealth

Several large investors have recently made changes to their positions in the company. Bleichroeder LP acquired a new position in MDxHealth during the 4th quarter valued at about $18,643,000. Altium Capital Management LP acquired a new stake in shares of MDxHealth in the 4th quarter valued at approximately $344,000. Ghisallo Capital Management LLC acquired a new stake in shares of MDxHealth in the 4th quarter valued at approximately $190,000. Finally, Perkins Capital Management Inc. acquired a new stake in shares of MDxHealth in the 4th quarter valued at approximately $857,000. Institutional investors own 18.16% of the company’s stock.

MDxHealth Stock Performance

NASDAQ:MDXH traded down $0.16 during trading hours on Thursday, hitting $6.84. 2,717 shares of the company traded hands, compared to its average volume of 27,924. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.05 and a quick ratio of 3.94. The firm has a 50-day moving average of $7.49 and a 200 day moving average of $8.04. MDxHealth has a twelve month low of $6.20 and a twelve month high of $13.17.

MDxHealth (NASDAQ:MDXHGet Rating) last announced its quarterly earnings results on Wednesday, April 27th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.50. The business had revenue of $6.11 million during the quarter, compared to the consensus estimate of $8.85 million. On average, sell-side analysts expect that MDxHealth will post -2.09 earnings per share for the current year.

Analysts Set New Price Targets

MDXH has been the subject of several recent analyst reports. BTIG Research reissued a “buy” rating and set a $13.00 price objective on shares of MDxHealth in a report on Friday, April 29th. Oppenheimer reissued an “outperform” rating and issued a $18.00 target price on shares of MDxHealth in a research report on Monday, July 18th.

MDxHealth Company Profile

(Get Rating)

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications.

Featured Articles

Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.